X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bayer has granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra. Vericiguat, a sGC stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction.
Lead Product(s): Vericiguat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Gantra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 05, 2024
Details:
The collaboration aims to develop next-generation sequencing-based companion diagnostic assays to identify patients who may benefit from Bayer’s portfolio of precision cancer therapies, including Nubeqa (darolutamide), a medication for certain prostate cancers (mHSPC, nmCRPC).
Lead Product(s): Darolutamide
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Thermo Fisher Scientific
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 20, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: BAY3427080
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Lead Product(s): Bemdaneprocel
Therapeutic Area: Neurology Product Name: BRT-DA01
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Under the agreement, BridgeBio grants Bayer exclusive license to commercialize acoramidis, an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of TTR, as a treatment for patients with ATTR-CM in Europe.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Licensing Agreement March 04, 2024
Details:
Through the acquisition, Bayer leverages the commercialization rights of AG10 (acoramidis) rights for European markets. It is a highly potent and selective small molecule, orally administered transthyretin stabilizer for the treatment of patients suffering from ATTR CM.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 04, 2024
Details:
BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor, which is being evaluated for the treatment of non-small cell lung cancer harboring HER2 activating mutations.
Lead Product(s): BAY2927088
Therapeutic Area: Oncology Product Name: BAY2927088
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
BAY3018250 is an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody. It is being evaluated for the treatment of patients with deep vein thrombosis.
Lead Product(s): BAY3018250
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BAY3018250
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
AB-1002 (NAN-101) is an investigational gene therapy, which is currently under phase 2 clinical development for the treatment of congestive heart failure.
Lead Product(s): NAN-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AB-1002
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: AskBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is being evaluated in phase 3 clinical trials for the treatment of neovascular (wet) age-related macular degeneration.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
